Group items tagged

For Dr. John Evans, growing a strong biotechnology industry is much the same: cities must provide a nurturing environment where science and business can thrive together.

That's why Evans, former president of the University of Toronto and current chairman of Torstar Corp., is spearheading the $345-million Medical and Related Science initiative, or MaRS--a petri dish of sorts for commercializing science research. "A lot of intellectual property is being commercialized outside Canada," says Evans. "I think we've been slow in realizing just how important technology developments are to the economic future of the country. MaRS is an attempt to give this a kick into a higher gear." The centrepiece of the MaRS plan, which will officially launch May 12, is a 1.3-million-square-foot, five-building complex in downtown Toronto that will provide office and lab space for small and medium-size companies and incubators, including the not-for-profit Toronto Biotechnology Commercialization Centre. While Evans is reluctant to limit its scope, MaRS will generally focus on health-related technologies, from new drugs and genetic treatments to medical devices and imaging software. Branded a "convergence centre," it will also house a careful mix of support services: intellectual property lawyers, accountants, marketing experts, government funding organizations and venture capital financiers. Plus, start-ups will have access to all the latest equipment on site. For instance, MaRS is in talks with MDS Sciex to supply mass spectrometers, used in proteomics research.

But MaRS will be more than just a New Economy real estate development. Evans's intention is to funnel tenants' rent money into services--such as entrepreneurship seminars and angel-matching programs--that MaRS will offer to the broader biotech community. That's why MaRS's location is key: the centre will be built in the heart of what Toronto has dubbed the "Discovery District," a two-square-kilometre chunk of the downtown core, encompassing U of T and four major hospitals. From there, MaRS hopes to act as a network hub across Ontario, with links to research-intensive universities. "None of them," says Evans, "have the critical mass to put it all together on their own."

Ross Wallace, director of strategic partnerships at the MarS Centre, which brings together scientists, entrepreneurs and investors, has seen a lot of P3s at their best.

Wallace was as baffled as everybody else. But he believed a business model could be created that would connect medical discoveries coming out of universities and government labs with the money available from private foundations.A year ago, he won one of six fellowships offered by the Walter and Duncan Gordon Foundation to young people eager to tackle global problems. His research led in an unexpected – and welcome – direction. It turned out that he didn't have to invent a new business model. One already existed."I found some really exciting collaboration going on," he said. "A new breed of partnerships had emerged that completely transformed the development and delivery of pharmaceuticals for neglected diseases."

So Wallace redefined his task. He would look for ways to bolster these fledgling P3s.They have a very short history. The first grew out of a program launched by the World Bank in 1999 to pull together money and talent for research on tropical diseases. But it remained buried within the global bureaucracy.

Probably most impressive was The MaRS Centre - an old hospital converted into a non-profit innovation centre connecting science, technology and social entrepreneurs with business skills, networks and capital. The building is undeniably cool. Located in Toronto’s “Discovery District” -- two square kilometres have been designated as the city’s center of innovation. The MaRS Centre is a gateway of sorts to Canada’s largest concentration of scientific research. It’s anchored by major teaching hospitals, the University of Toronto and more than two dozen affiliated research institutes.

MaRS Centre from the outside

MaRS was created in 2000. The founding group raised significant capital (almost $100 million from all three levels of government and both institutional and individual private sector donors and an additional $130 million of debt and credit lease instruments were also secured) to support the development. What’s so clear is that leadership to drive public/private sector collaboration is required to effect real change. Many credit Ontario Premier Dalton McGuinty for helping to not only create the MaRS Centre but also invigorate the region as a whole.

What is this creative economy? It is an economic system that relies most on ideas to serve as its major capital, instead of services or physical capital. Take Google for example. In an economy based on ideas, the potentialfor breakaway successes like Google is far greater.

According to Richard Florida’s The Rise of the Creative Class: And How it’s Transforming Work, Leisure,Community and Everyday Life, members of the creative class are very different from those who are employed in the manufacturing, service or agriculture industries. They contribute to our economy primarily by producing the new forms and ideas exploited by our various industries and decision-makers.   What Florida terms the “super creative core” of this new class includes “scientists and engineers, university professors, poets and novelists, artists, entertainers, actors, designersand architects, as well as the ‘thought leadership’ of modern society: non-fiction writers, editors, cultural figures, think-tank researchers, analysts and other opinion-makers.”

What sets a creative city apart from a non-creative city? Florida proposes that it is the “three Ts of economic development”: technology, talent and tolerance.

MaRS Innovation and the Samuel Lunenfeld Research Institute of Mount Sinai Hospital are pleased to announce that they have entered into an agreement to collaboratively initiate commercialization of an umbilical cord stem cell technology for potential treatment in cardiovascular disease, diabetes and neurological disorders.

With the Toronto area identified as a world-leading cluster in stem cell research, we are extremely excited to have identified this technology as our first commercialization opportunity,” said Dr. Rafi Hofstein, President and CEO of MaRS Innovation.

MaRS Innovation, along with the inventors and Mount Sinai, will initially focus on the diabetes application for the technology, as research has demonstrated that these cells uniquely secrete insulin in response to glucose, thereby mimicking the “normal” physiological state.

Toronto, where a small firm is using 21st-century software to create maps with similar goals - the containment of disease - by showing infection patterns that can be understood at a glance.

Toronto, where a small firm is using 21st-century software to create maps with similar goals - the containment of disease - by showing infection patterns that can be understood at a glance.

There's nothing wrong with Infonaut using the H1N1 flu outbreak to gain exposure, as long as the company is careful in the tone it takes, said John Lute, president of Toronto communications firm Lute and Co.